{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:52:21Z","timestamp":1777870341578,"version":"3.51.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jiangsu Research Hospital Association for Precision Medication","award":["JY202013"],"award-info":[{"award-number":["JY202013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hydroxychloroquine (HCQ) is recommended for Chinese patients with immunoglobulin A nephropathy (IgAN). However, the relationship between HCQ blood concentration and the therapeutic effect for IgAN has not yet been defined. This study investigates the optimal and efficacious range of HCQ blood concentrations in Chinese patients with IgAN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seventy-three patients with biopsy-proven IgAN who were at risk of progression were included in this study. Thirty-eight patients with IgAN were treated with HCQ plus an optimized renin\u2013angiotensin\u2013aldosterone system inhibitor (RAASi), and thirty-five patients received only RAASi. Blood HCQ concentration and 24-h proteinuria were examined at three and six months after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The baseline proteinuria levels were comparable between the RAASi and HCQ groups. The HCQ group had lower 24-h proteinuria than the RAASi group three months after treatment, though the difference was not significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.38). After six months, the median proteinuria level was significantly lower in the HCQ group than in the RAASi group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The percentage reduction in 24-h proteinuria in the HCQ group was greater than that in the RAASi group at three (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) and six months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Hydroxychlorquine blood concentration and efficacy were positively correlated at three months (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.428,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) and six months (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.48,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Moreover, the optimal blood concentration of HCQ for three-month efficacy was 418.96\u00a0ng\/mL and that for six-month efficacy was 582.48\u00a0ng\/mL. No serious adverse events were reported during HCQ treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hydroxyhloroquine safely reduces proteinuria in Chinese patients with IgAN. The efficacy of HCQ is positively correlated with its blood concentration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-024-02029-z","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T18:01:48Z","timestamp":1721844108000},"page":"2201-2208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hydroxychloroquine blood concentrations and effects in Chinese patients with IgA nephropathy"],"prefix":"10.1093","volume":"37","author":[{"given":"Ting","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaotong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"4","key":"2029_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"JC Rodrigues","year":"2017","unstructured":"Rodrigues JC, Haas M, Reich HN (2017) IgA nephropathy. Clin J Am Soc Nephrol 12(4):677\u2013686. https:\/\/doi.org\/10.2215\/CJN.07420716","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4S","key":"2029_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4S):S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"issue":"23","key":"2029_CR3","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR et al (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373(23):2225\u20132236. https:\/\/doi.org\/10.1056\/NEJMoa1415463","journal-title":"N Engl J Med"},{"issue":"5","key":"2029_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","volume":"23","author":"KD Rainsford","year":"2015","unstructured":"Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF (2015) Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23(5):231\u2013269. https:\/\/doi.org\/10.1007\/s10787-015-0239-y","journal-title":"Inflammopharmacology"},{"issue":"3","key":"2029_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105143","volume":"88","author":"A Dima","year":"2021","unstructured":"Dima A, Jurcut C, Arnaud L (2021) Hydroxychloroquine in systemic and autoimmune diseases: where are we now? Joint Bone Spine 88(3):105143. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105143","journal-title":"Joint Bone Spine"},{"issue":"1","key":"2029_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","volume":"74","author":"LJ Liu","year":"2019","unstructured":"Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, Sui GL, Chen YQ, Lv JC, Zhang H (2019) Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 74(1):15\u201322. https:\/\/doi.org\/10.1053\/j.ajkd.2019.01.026","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2029_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40620-021-00988-1","volume":"35","author":"C Tang","year":"2022","unstructured":"Tang C, Lv JC, Shi SF, Chen YQ, Liu LJ, Zhang H (2022) Long-term safety and efficacy of hydroxychloroquine in patients with IgA nephropathy: a single-center experience. J Nephrol 35(2):429\u2013440. https:\/\/doi.org\/10.1007\/s40620-021-00988-1","journal-title":"J Nephrol"},{"issue":"5","key":"2029_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/acr.24155","volume":"73","author":"S Garg","year":"2021","unstructured":"Garg S, Unnithan R, Hansen KE, Costedoat-Chalumeau N, Bartels CM (2021) Clinical significance of monitoring hydroxychloroquine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 73(5):707\u2013716. https:\/\/doi.org\/10.1002\/acr.24155","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2029_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000841","author":"S Fasano","year":"2023","unstructured":"Fasano S, Messiniti V, Iudici M, Coscia MA, Ciccia F (2023) Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus. Lupus Sci Med. https:\/\/doi.org\/10.1136\/lupus-2022-000841","journal-title":"Lupus Sci Med"},{"issue":"9","key":"2029_CR10","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/ndt\/gfx318","volume":"33","author":"C Cunha","year":"2018","unstructured":"Cunha C, Alexander S, Ashby D, Lee J, Chusney G, Cairns TD, Lightstone L (2018) Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? Nephrol Dial Transplant 33(9):1604\u20131610. https:\/\/doi.org\/10.1093\/ndt\/gfx318","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"2029_CR11","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1002\/art.22156","volume":"54","author":"N Costedoat-Chalumeau","year":"2006","unstructured":"Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, Frances C, Wechsler B, du Huong LT, Ghillani P et al (2006) Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 54(10):3284\u20133290. https:\/\/doi.org\/10.1002\/art.22156","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2029_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL et al (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367(1):20\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1114248","journal-title":"N Engl J Med"},{"issue":"4","key":"2029_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ekir.2017.02.003","volume":"2","author":"Q Cai","year":"2017","unstructured":"Cai Q, Xie X, Wang J, Shi S, Liu L, Chen Y, Lv J, Zhang H (2017) Severe adverse effects associated with corticosteroid treatment in patients with IgA nephropathy. Kidney Int Rep 2(4):603\u2013609. https:\/\/doi.org\/10.1016\/j.ekir.2017.02.003","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2029_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s12882-020-02141-9","volume":"21","author":"C Tang","year":"2020","unstructured":"Tang C, Lv JC, Shi SF, Chen YQ, Liu LJ, Zhang H (2020) Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study. BMC Nephrol 21(1):469. https:\/\/doi.org\/10.1186\/s12882-020-02141-9","journal-title":"BMC Nephrol"},{"issue":"7","key":"2029_CR15","first-page":"1656","volume":"27","author":"SE Tett","year":"2000","unstructured":"Tett SE, Cutler DJ, Beck C, Day RO (2000) Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis\u2013a prospective, dose ranging study. J Rheumatol 27(7):1656\u20131660","journal-title":"J Rheumatol"},{"issue":"11","key":"2029_CR16","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3899\/jrheum.150379","volume":"42","author":"L Durcan","year":"2015","unstructured":"Durcan L, Clarke WA, Magder LS, Petri M (2015) Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol 42(11):2092\u20132097. https:\/\/doi.org\/10.3899\/jrheum.150379","journal-title":"J Rheumatol"},{"issue":"11","key":"2029_CR17","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1136\/annrheumdis-2012-202322","volume":"72","author":"N Costedoat-Chalumeau","year":"2013","unstructured":"Costedoat-Chalumeau N, Galicier L, Aumaitre O, Frances C, Le Guern V, Liote F, Smail A, Limal N, Perard L, Desmurs-Clavel H et al (2013) Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 72(11):1786\u20131792. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202322","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2029_CR18","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1002\/art.39194","volume":"67","author":"M Jallouli","year":"2015","unstructured":"Jallouli M, Galicier L, Zahr N, Aumaitre O, Frances C, Le Guern V, Liote F, Smail A, Limal N, Perard L et al (2015) Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol 67(8):2176\u20132184. https:\/\/doi.org\/10.1002\/art.39194","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"2029_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1177\/0961203317727601","volume":"27","author":"H Al-Rawi","year":"2018","unstructured":"Al-Rawi H, Meggitt SJ, Williams FM, Wahie S (2018) Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus. Lupus 27(5):847\u2013852. https:\/\/doi.org\/10.1177\/0961203317727601","journal-title":"Lupus"},{"issue":"1","key":"2029_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/art.39402","volume":"68","author":"JY Lee","year":"2016","unstructured":"Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, Jung SH, Park SW, Chung YJ, Park SH (2016) Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol 68(1):184\u2013190. https:\/\/doi.org\/10.1002\/art.39402","journal-title":"Arthritis Rheumatol"},{"issue":"15","key":"2029_CR21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2217\/pgs-2023-0124","volume":"24","author":"M Biswas","year":"2023","unstructured":"Biswas M, Sukasem C (2023) Pharmacogenomics of chloroquine and hydroxychloroquine: current evidence and future implications. Pharmacogenomics 24(15):831\u2013840. https:\/\/doi.org\/10.2217\/pgs-2023-0124","journal-title":"Pharmacogenomics"},{"issue":"1","key":"2029_CR22","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1080\/0886022X.2021.2000875","volume":"43","author":"G Stefan","year":"2021","unstructured":"Stefan G, Mircescu G (2021) Hydroxychloroquine in IgA nephropathy: a systematic review. Ren Fail 43(1):1520\u20131527. https:\/\/doi.org\/10.1080\/0886022X.2021.2000875","journal-title":"Ren Fail"},{"issue":"1","key":"2029_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12882-019-1488-6","volume":"20","author":"YZ Yang","year":"2019","unstructured":"Yang YZ, Chen P, Liu LJ, Cai QQ, Shi SF, Chen YQ, Lv JC, Zhang H (2019) Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study. BMC Nephrol 20(1):297. https:\/\/doi.org\/10.1186\/s12882-019-1488-6","journal-title":"BMC Nephrol"},{"issue":"3","key":"2029_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/RHU.0000000000000502","volume":"23","author":"JF Restrepo","year":"2017","unstructured":"Restrepo JF, Del Rincon I, Molina E, Battafarano DF, Escalante A (2017) Use of hydroxychloroquine is associated with improved lipid profile in rheumatoid arthritis patients. J Clin Rheumatol 23(3):144\u2013148. https:\/\/doi.org\/10.1097\/RHU.0000000000000502","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"2029_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","volume":"77","author":"C Rempenault","year":"2018","unstructured":"Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, Hua C (2018) Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 77(1):98\u2013103. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211836","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2029_CR26","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, Academy A, of Ophthalmology, (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 123(6):1386\u20131394. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.058","journal-title":"Ophthalmology"},{"issue":"3","key":"2029_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","volume":"16","author":"C Ponticelli","year":"2017","unstructured":"Ponticelli C, Moroni G (2017) Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf 16(3):411\u2013419. https:\/\/doi.org\/10.1080\/14740338.2017.1269168","journal-title":"Expert Opin Drug Saf"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02029-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-02029-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02029-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:40Z","timestamp":1777564420000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/8\/2201\/8306360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["2029"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-02029-z","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"27 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed and approved by the Medical Ethics Committee of the Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University (approval number: 2021-074-05). All participants provided written informed consent prior to their enrollment in the study. This trial was registered at\n                      \n                      (chiCTR2100052910).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study was conducted in accordance with the principles contained in the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"All participants provided written informed consent prior to their enrollment in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent and consent to participate"}}]}}